Cost-effectiveness of teduglutide in adult patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria.

CONCLUSIONS: Teduglutide does not meet a traditional cost-effectiveness threshold as treatment for PN reduction in adult patients with short bowel syndrome compared with standard intestinal rehabilitation. Subpopulations that demonstrate maximum benefit could be cost-saving, and complete nonuse could lead to financial loss. Teduglutide becomes economically reasonable only if its cost is substantially reduced.
PMID: 31665212 [PubMed - as supplied by publisher]

Source: The American Journal of Clinical Nutrition - October 29, 2019 Category: Nutrition Authors: Raghu VK, Binion DG, Smith KJ Tags: Am J Clin Nutr Source Type: research